HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

pentetreotide (OctreoScan)

Subscribe to New Research on pentetreotide

an indium-labelled somatostatin analog for imaging of somatostatin receptor positive tumours; OctreoScan is tradename for indium In 111 pentetreotide

Also Known As:

OctreoScan; indium In 111 pentetreotide; 111 In -pentetreotide; 111-indium-pentetreotide; In-111 pentetreotide; indium-pentetreotide; L-Cysteinamide, N-(2-((2-(bis(carboxymethyl)amino)ethyl)(carboxymethyl)amino)ethyl)-N-(carboxymethyl)glycyl-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (3-8)-disulfide, (R-,(R*,R*))-

Networked: 295 relevant articles (19 outcomes, 23 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Toubanakis, Christos: 4 articles (01/2011 - 05/2005)
2.	Nikou, George C: 4 articles (01/2011 - 05/2005)
3.	Krenning, Eric P: 4 articles (05/2010 - 04/2003)
4.	Pacak, Karel: 3 articles (08/2015 - 09/2002)
5.	Sarmiento, Juan M: 3 articles (07/2015 - 01/2003)
6.	Menda, Yusuf: 3 articles (08/2014 - 02/2004)
7.	Delpassand, Ebrahim S: 3 articles (01/2014 - 06/2008)
8.	Carrasquillo, Jorge A: 3 articles (08/2012 - 09/2002)
9.	Anthony, Lowell B: 3 articles (06/2012 - 04/2002)
10.	Mallas, Elias: 3 articles (01/2011 - 05/2005)

Related Diseases

1.	Neoplasms (Cancer) 12/15/1997 - "This study explores the efficacy of OctreoScan and a newly developed handheld gamma detector probe (H-probe2) for the localization of neuroendocrine abdominal tumors. " 10/01/1996 - "The aim of this study was to evaluate the ability of Octreoscan scintigraphy to detect such tumors. " 01/01/1994 - "The results are the following: 2 patients of group A (secreting tumors) had a positive three-step ISG, whereas all the patients but one of the same group had a positive pentetreotide study; all the patients of group B (nonsecreting tumors) had a positive three-step ISG and 4 had a positive pentetreotide scintigraphy. " 07/01/2015 - "The sensitivity of Octreoscan versus PET varied similarly when analyzed by WHO tumor grade: Grade 1 (79 vs. 52 %; p = 0.16), Grade 2 (85 vs. 86 %; p = not significant), and Grade 3 (57 vs. 100 %; p = 0.02). " 09/01/2014 - "111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors."
2.	Neoplasm Metastasis (Metastasis) 07/01/2005 - "OCTREOSCAN revealed a solitary lesion in the right hepatic lobe, not detected by all the previous studies, while it detected, as a whole, the primary lesion in 10/11 (91%), and the metastases in 3/4 (75%) pts. In 7/11 (63.6%) the primary lesion was located in the pancreas, whereas in the rest it was in the duodenum or retroperitoneum. " 05/01/2010 - "Octreoscan and whole body CT scan confirmed a locally advanced disease, in the absence of metastases. " 01/01/2010 - "An octreoscan prior to surgical procedures revealed multiple osseous and intra-hepatic metastases. " 01/01/2008 - "OctreoScan showed avid uptake in 77.8% of patients with hepatic metastases. " 01/01/2008 - "As in our case, new scintigraphic methods, such as 111-In-pentetreotide scintigraphy (Octreoscan), may occasionally reveal 123-I-metaiodobenzylguanidine-negative distant metastases and help to establish an early diagnosis of malignancy. "
3.	Carcinoid Tumor (Carcinoid) 01/01/1999 - "We conclude that: 1. the octreoscan scintigraphy in the follow-up of resected carcinoids can give false-positive results and 2. in consequence, the mediastinoscopy is a discriminating investigation in case of mediastinal lymph nodes disease." 02/01/2013 - "The scintigraphic investigation of neuroendocrine tumours such as carcinoids has depended on standard techniques such as I-metaiodobenzylguanidine and In-pentetreotide imaging. " 10/01/2010 - "The bronchial biopsy confirmed that it was a typical bronchial carcinoid and the octreoscan showed a single focus of high uptake coinciding with this lesion. " 09/01/2008 - "This case illustrates that hardware SPECT/CT fusion imaging utilizing indium-111 pentetreotide to evaluate metastatic carcinoid tumors can be useful. " 06/01/2007 - "Follow-up of a carcinoid tumor in the middle ear by in-111 pentetreotide scintigraphy."
4.	Carcinoma (Carcinomatosis) 05/01/2004 - "The authors present two cases of gastrin-producing carcinoma demonstrated by scintigraphy with In-111 pentetreotide. " 04/01/2005 - "Our preliminary results seem to demonstrate the efficacy of octreotide as adjuvant therapy in large cell neuroendocrine carcinomas of the lung when results of preoperative indium In-111 pentetreotide scintigraphy were positive. " 09/01/1997 - "The authors present the cases of two patients who underwent somatostatin receptor scintigraphy (SSRS) using In-111 pentetreotide: one for the study of suspected paraneoplastic ACTH hypersecretion, and the other for a restaging of breast carcinoma with neuroendocrine features. " 05/01/1997 - "111In-pentetreotide is unlikely to replace 123I-MIBG as a first-line routine diagnostic scintigraphic modality; compared to pentetreotide or MIBG, (V)DMSA seems to be highly sensitive only in medullary thyroid carcinomas." 03/01/2011 - "Two thymomas were at stage I, 1 thymoma and 1 thymic carcinoma at stage II, 1 insular carcinoma of presumably thymic origin at stage IV, and 1 thymic carcinoid at stage IV. OctreoScan consistently accumulated in primary and/or metastatic sites of thymic tumors while no radiotracer uptake was detected in the 2 patients with benign thymic hyperplasia. "
5.	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/01/2008 - "Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors." 01/01/2012 - "To study the long term benefits, toxicity and survival rate in patients with neuroendocrine tumors receiving multiple cycles of high activity In-111 Pentetreotide therapy. " 12/01/2001 - "The study describes the results of Octreoscan SPET (OCTSPET) qualitative and semi-quantitative evaluation in 38 patients with suspected pancreatic neuroendocrine tumors. " 07/01/2015 - "Clinicians may order Octreoscan or positron emission tomography (PET) scan for staging patients with neuroendocrine tumors (NETs). " 07/01/2015 - "Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach."

Related Drugs and Biologics

1.	Octreotide (Sandostatin)
2.	Somatostatin Receptors (Somatostatin Receptor)
3.	Somatostatin (Somatotropin Release-Inhibiting Factor)
4.	pentetreotide (OctreoScan)
5.	3-Iodobenzylguanidine (Iobenguane)
6.	Adrenocorticotropic Hormone (ACTH)
7.	Indium
8.	Chromogranin A
9.	Growth Hormone (Somatotropin)
10.	Guanidine (Guanidine Nitrate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Thyroidectomy
4.	Intravenous Injections
5.	Transplants (Transplant)